ABOUT THIS STUDY
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
Pfizer Clinical Trials Contact Center
1-800-718-1021
- Osteoarthritis of the knee according to ACR criteria with a Kellgren-Lawrence x-ray grade of 2.
- Unwilling or unable to take non-opiate pain medications, for whom non-opiate pain medications have not provided adequate pain relief or are candidates for knee injections arthroplasty or replace surgery.
- Pain level and function levels as required by the protocol at Screening and Baseline.
- Willing to discontinue pain medications (acetaminophen will be permitted up to a certain level) before and during the study.
- Must agree to the contraceptive requirements of the protocol if applicable.
- Must agree to the treatment plan, scheduled visits, and procedures of the protocol.
- Pregnancy or intent to become pregnant during the study
- BMI greater than 39
- other severe pain, significant cardiac, neurological or psychological conditions, or
above the protocol limits for laboratory and blood pressure results
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
- Phoenix, Arizona
- Danbury, Connecticut
- Stamford, Connecticut
- Newark, Delaware
- Clearwater, Florida
- Clearwater, Florida
- DeLand, Florida
- DeLand, Florida
- Delray Beach, Florida
- Delray Beach, Florida
- Jacksonville, Florida
- Miami, Florida
- Miami, Florida
- Miami, Florida
- Orlando, Florida
- Palm Harbor, Florida
- Pembroke Pines, Florida
- Pinellas Park, Florida
- Port Orange, Florida
- Saint Petersburg, Florida
- West Palm Beach, Florida
- Atlanta, Georgia
- Decatur, Georgia
- Fort Valley, Georgia
- Marietta, Georgia
- Woodstock, Georgia
- Woodstock, Georgia
- Boise, Idaho
- Springfield, Illinois
- South Bend, Indiana
- South Bend, Indiana
- Valparaiso, Indiana
- Lexington, Kentucky
- Lexington, Kentucky
- Louisville, Kentucky
- Baton Rouge, Louisiana
- Baton Rouge, Louisiana
- Monroe, Louisiana
- Auburn, Maine
- Baltimore, Maryland
- Frederick, Maryland
- Wheaton, Maryland
- Mansfield, Massachusetts
- Peabody, Massachusetts
- Worcester, Massachusetts
- Ann Arbor, Michigan
- Saint Clair Shores, Michigan
- Edina, Minnesota
- Edina, Minnesota
- Saint Louis, Missouri
- Las Vegas, Nevada
- Berlin, New Jersey
- Albuquerque, New Mexico
- Albuquerque, New Mexico
- Elmira, New York
- Ithaca, New York
- New York, New York
- Plainview, New York
- Rochester, New York
- Charlotte, North Carolina
- Greensboro, North Carolina
- Raleigh, North Carolina
- Winston-Salem, North Carolina
- Cincinnati, Ohio
- Middleburg Heights, Ohio
- Zanesville, Ohio
- Oklahoma City, Oklahoma
- Beaverton, Oregon
- Portland, Oregon
- Portland, Oregon
- Bethlehem, Pennsylvania
- Downingtown, Pennsylvania
- Duncansville, Pennsylvania
- Rapid City, South Dakota
- Johnson City, Tennessee
- Austin, Texas
- Dallas, Texas
- San Antonio, Texas
- San Antonio, Texas
- San Antonio, Texas
- Charlottesville, Virginia
- Yakima, Washington
- Anniston, Alabama
- Mesa, Arizona
- Paradise Valley, Arizona
- Peoria, Arizona
- Phoenix, Arizona
- Phoenix, Arizona
- Tempe, Arizona
- Tucson, Arizona
- Tuscon, Arizona
- Hot Springs, Arkansas
- Beverly Hills, California
- Fresno, California
- Huntington Beach, California
- Sacramento, California
- Thousand Oaks, California
- Stamford, Connecticut
- Newark, Delaware
- Clearwater, Florida
- Clearwater, Florida
- Coral Gables, Florida
- DeLand, Florida
- Jacksonville, Florida
- Longwood, Florida
- Miami, Florida
- Palm Harbor, Florida
- Pembroke Pines, Florida
- Port Orange, Florida
- Tamarac, Florida
- West Palm Beach, Florida
- Atlanta, Georgia
- Decatur, Georgia
- Marietta, Georgia
- Woodstock, Georgia
- Woodstock, Georgia
- Boise, Idaho
- Chicago, Illinois
- Chicago, Illinois
- Morton Grove, Illinois
- Morton, Illinois
- Springfield, Illinois
- Valparaiso, Indiana
- Ames, Iowa
- West Des Moines, Iowa
- Wichita, Kansas
- Louisville, Kentucky
- Baton Rouge, Louisiana
- Auburn, Maine
- Frederick, Maryland
- Wheaton, Maryland
- Worcester, Massachusetts
- St. Clair Shores, Michigan
- Edina, Minnesota
- St. Louis, Missouri
- Omaha, Nebraska
- Las Vegas,, Nevada
- Las Vegas, Nevada
- Berlin, New Jersey
- Albuquerque, New Mexico
- Albuquerque, New Mexico
- New York, New York
- Rochester, New York
- Roslyn, New York
- Charlotte, North Carolina
- Greensboro, North Carolina
- Fargo, North Dakota
- Cincinnati, Ohio
- Middleburg Heights, Ohio
- Zanesville, Ohio
- Oklahoma City, Oklahoma
- Duncansville, Pennsylvania
- West Reading, Pennsylvania
- Mount Pleasant, South Carolina
- Rapid City, South Dakota
- Johnson City, Tennessee
- Kingsport, Tennessee
- Austin, Texas
- Dallas, Texas
- Houston, Texas
- Houston, Texas
- San Antonio, Texas
- San Antonio, Texas
- Orem, Utah
- Norfolk, Virginia
- Portsmouth, Virginia
- Yakima, Washington
Descriptive Information | |||||||
---|---|---|---|---|---|---|---|
Brief Title ICMJE | Tanezumab in Osteoarthritis of the Knee | ||||||
Official Title ICMJE | A PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER STUDY OF THE ANALGESIC EFFICACY AND SAFETY OF TANEZUMAB IN PATIENTS WITH OSTEOARTHRITIS OF THE KNEE | ||||||
Brief Summary | Test the efficacy and safety of 3 doses in Osteoarthritis of the knee in patients. | ||||||
Detailed Description | Not Provided | ||||||
Study Type ICMJE | Interventional | ||||||
Study Phase ICMJE | Phase 3 | ||||||
Study Design ICMJE | Allocation: Randomized Intervention Model: Parallel Assignment Masking: Double (Participant, Investigator) Primary Purpose: Treatment | ||||||
Condition ICMJE |
| ||||||
Intervention ICMJE |
| ||||||
Study Arms ICMJE |
| ||||||
Publications * |
| ||||||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | |||||||
Recruitment Information | |||||||
Recruitment Status ICMJE | Completed | ||||||
Actual Enrollment ICMJE | 697 | ||||||
Original Estimated Enrollment ICMJE | 600 | ||||||
Actual Study Completion Date ICMJE | January 14, 2010 | ||||||
Actual Primary Completion Date | August 24, 2009 (Final data collection date for primary outcome measure) | ||||||
Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
| ||||||
Sex/Gender ICMJE |
| ||||||
Ages ICMJE | 18 Years to 99 Years (Adult, Older Adult) | ||||||
Accepts Healthy Volunteers ICMJE | No | ||||||
Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | ||||||
Listed Location Countries ICMJE | United States | ||||||
Removed Location Countries | |||||||
Administrative Information | |||||||
NCT Number ICMJE | NCT00733902 | ||||||
Other Study ID Numbers ICMJE | A4091011 P3 OA KNEE ( Other Identifier: Alias Study Number ) | ||||||
Has Data Monitoring Committee | Yes | ||||||
U.S. FDA-regulated Product | Not Provided | ||||||
IPD Sharing Statement ICMJE |
| ||||||
Responsible Party | Pfizer | ||||||
Study Sponsor ICMJE | Pfizer | ||||||
Collaborators ICMJE | Not Provided | ||||||
Investigators ICMJE |
| ||||||
PRS Account | Pfizer | ||||||
Verification Date | February 2021 | ||||||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |